Stockscreener 앱 받기
0.436
5.22%
-0.024
시장 영업 전:
.42
-0.016
-3.67%
전일 마감가:
$0.46
열려 있는:
$0.4577
하루 거래량:
68,662
Relative Volume:
0.29
시가총액:
$17.26M
수익:
-
순이익/손실:
$-58.52M
주가수익비율:
-0.2086
EPS:
-2.09
순현금흐름:
$-45.03M
1주 성능:
-6.38%
1개월 성능:
-11.45%
6개월 성능:
-43.45%
1년 성능:
-70.93%
1일 변동 폭
$0.4263
$0.47
1주일 범위
$0.4263
$0.4919
52주 변동 폭
$0.224
$1.8199
Nextcure Inc Stock (NXTC) Company Profile
명칭
Nextcure Inc
전화
240-399-4900
주소
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
NXTC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
0.436 | 17.26M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-03-05 | 업그레이드 | Truist | Hold → Buy |
| 2021-01-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-07-16 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-07-13 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-13 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-06-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 개시 | JMP Securities | Mkt Outperform |
| 2020-03-24 | 개시 | The Benchmark Company | Buy |
| 2020-03-02 | 개시 | ROTH Capital | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-05 | 개시 | Needham | Buy |
| 2019-11-26 | 개시 | BTIG Research | Buy |
| 2019-07-09 | 개시 | BofA/Merrill | Buy |
| 2019-06-03 | 개시 | Morgan Stanley | Overweight |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Nextcure Inc 주식(NXTC)의 최신 뉴스
Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com
Market Recap: Next Technology Holding Inc (NXTT)’s Positive Momentum, Closing at 1.40 - DWinneX
Market Highlights: Nextcure Inc (NXTC) Ends on a Low Note at 0.50 - DWinneX
NextCure tanks as it teams up with Simcere on novel ADC - The Pharma Letter
NextCure and Simcere partner to develop SIM0505 for solid tumours - Yahoo Finance
NextCure partners with Simcere Zaiming on cancer drug development By Investing.com - Investing.com South Africa
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal - BioSpace
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline - Asianet Newsable
NextCure And Simcere Zaiming Partner To Develop CDH6-Targeting ADC SIM0505 For Solid Tumors - Nasdaq
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - MarketScreener
Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure - marketscreener.com
NextCure Enters Licensing Agreement with Simcere Zaiming - TipRanks
NextCure (NXTC) Partners with Simcere Zaiming for Innovative Cancer Treatment | NXTC Stock News - GuruFocus
NextCure partners with Simcere Zaiming on cancer drug development - Investing.com Australia
Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6 - marketscreener.com
Simcere Enters Strategic License Agreement with NextCure for Oncology Advancements - TipRanks
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire
NextCure Lands Massive $745M Deal for Revolutionary Cancer Drug: Phase 1 Trials Starting Q3 2025 - Stock Titan
Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail
Billionaire Terry Smith, "the English Warren Buffett," Is Selling Meta Platforms and Microsoft and Buying This Stock That's Trouncing the Market in 2025 - The Globe and Mail
Is Lucid Stock a Millionaire-Maker? - The Globe and Mail
JD.com Underperforms Industry in 3 Months: Should You Book Profits? - The Globe and Mail
Whitbread (LON:WTB) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail
Can Shopify's Expanding Merchant Base Sustain Its Growth Momentum? - The Globe and Mail
Baidu Bets Big on AI: Is the Cloud Business Finally Paying Off? - The Globe and Mail
SFIX Q3 Loss Narrower Than Expected, FY25 Outlook Raised, Stock Up 8% - The Globe and Mail
COIN Outpaces Industry in 3 Months: Time to Buy the Stock? - The Globe and Mail
Power Corporation's President and Chief Executive Officer R. Jeffrey Orr to speak at the Scotiabank Financials Summit - The Globe and Mail
Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews
Best Dollar Store Stock to Buy: Dollar Tree or Dollar General? - The Globe and Mail
2 No-Brainer Growth Stocks to Buy in June - The Globe and Mail
The Next Stock I'm Buying? - The Globe and Mail
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 - Insider Monkey
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - The Manila Times
NextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025 - Nasdaq
First-in-Human Trial: NextCure's Revolutionary Cancer Drug Shows Promise Against 5 Hard-to-Treat Tumors - Stock Titan
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - Yahoo Finance
Here's How I'd Invest $10,000 Today - The Globe and Mail
Grant Williamson appointed as Canada Leader for Willis - The Globe and Mail
Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’ - The Globe and Mail
Is Enbridge Stock Still Worth Owning After Strong Q1 Earnings? - The Globe and Mail
Is Archer Aviation Stock (ACHR) a “Buy” Ahead of Q1 Earnings? - The Globe and Mail
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
NextCure Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NextCure Reports Q1 2025 Results and Strategic Progress - TipRanks
NextCure (NXTC) Advances LNCB74 Program in Phase 1 Study | NXTC Stock News - GuruFocus
NextCure, Inc. SEC 10-Q Report - TradingView
NextCure Expands Cancer Drug Trial to 13 Sites as Phase 1 ADC Study Hits Key Milestone - Stock Titan
NextCure Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Nextcure Inc (NXTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.42%
자본화:
|
볼륨(24시간):